Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 20/20 | 0.63 |
| ▸ | ADRB1 | P08588 | 16/20 | 0.63 |
| ▸ | ADRB3 | P13945 | 16/20 | 0.63 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5422340 | 1.00 | ADRB2 (0.63) | ADRB2ADRB1ADRB3ADRA1D | |
| SCHEMBL5430036 | 0.97 | ADRB2 (0.61) | ADRB2ADRB1ADRB3ADRA1D | |
| SCHEMBL5430030 | 0.97 | ADRB2 (0.61) | ADRB2ADRB1ADRB3ADRA1D | |
| SCHEMBL5428026 | 0.95 | ADRB2 (0.70) | ADRB2ADRB1ADRB3ADRA1D | |
| SCHEMBL5428019 | 0.95 | ADRB2 (0.70) | ADRB2ADRB1ADRB3ADRA1D | |
| SCHEMBL5278262 | 0.92 | ADRB2 (0.59) | ADRB2ADRB1ADRB3ADRA1D | |
| SCHEMBL5278274 | 0.92 | ADRB2 (0.59) | ADRB2ADRB1ADRB3ADRA1D | |
| SCHEMBL5434303 | 0.91 | ADRB2 (0.61) | ADRB2ADRB1ADRB3ADRA1D | |
| SCHEMBL5434294 | 0.91 | ADRB2 (0.61) | ADRB2ADRB1ADRB3ADRA1D | |
| Hydrochloric Acid SCHEMBL5385274 | 0.91 | ADRB2 (0.59) | ADRB2ADRB1ADRB3ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135490-A1 | Phenetanolamine derivatives | GLAXO GROUP LIMITED (GB) | 2007-06-14 | — | — | US | claimed |
| EP-1675821-A1 | PHENETANOLAMINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2006-07-05 | — | — | EP | claimed |
| WO-2005044787-A1 | PHENETANOLAMINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-05-19 | — | — | WO | claimed |
| US-20070135490-A1 | Phenetanolamine derivatives | GLAXO GROUP LIMITED (GB) | 2007-06-14 | — | — | US | disclosed |
| EP-1675821-A1 | PHENETANOLAMINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005044787-A1 | PHENETANOLAMINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135490-A1 | Phenetanolamine derivatives | ADRB2, ADRB1, ADRB3 | ADRB2 1/4885ADRB1 2/4885ADRB3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.